PECATI
OFFICIAL TITLE: A MULTICENTRIC, OPEN-LABEL, SINGLE ARM PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE COMBINATION OF PEMBROLIZUMAB AND LENVATINIB IN PRE-TREATED THYMIC CARCINOMA PATIENTS. PECATI.
PROJECT DETAILS
PRIMARY OBJECTIVE
● TO ASSESS THE EFFICACY OF PEMBROLIZUMAB AND LENVATINIB IN PRE-TREATED RELAPSED/RECURRENT B3-THYMOMA AND THYMIC CARCINOMA (TC) PATIENTS IN TERMS OF PROGRESSION FREE SURVIVAL (PFS) RATE AT 5 MONTHS.
SECUNDARY OBJETIVES
● TO ASSESS THE EFFICACY OF PEMBROLIZUMAB AND LENVATINIB IN PRE-TREATED ADVANCED B3-THYMOMA AND TC PATIENTS IN TERMS OF PFS, RESPONSE RATE (RR), DISEASE CONTROL RATE (DCR) DURATION OF RESPONSE (DOR), TUMOR SHRINKAGE AND OVERALL SURVIVAL (OS).
● TO ASSESS THE SAFETY AND TOXICITY PROFILE OF THE COMBINATION ACCORDING TO THE NATIONAL CANCER INSTITUTE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS VERSION 5.0 (CTCAE V.5.0).
PECATI AT CLINICALTRIALS.GOV
TUMOR TYPE
PHASE
N
SITES
COUNTRY
STATUS
Start-up
PECATI SITES
